🔗 Share this article The Global Health Body Sounds Warning Over Critical Shortage of Obesity Medications Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs including Wegovy can access them, states the global health agency as it releases its initial advice on the drugs. With more than one billion people worldwide currently classified as obese, it is advocating for increased and just availability to GLP-1 medication. Based on projections, more than two billion will be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be addressed with comprehensive and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major barriers to widespread access to the injections that can assist patients in reducing considerable body mass, notes the agency. Weight-Loss Drug Scarcity Even in the present best projected outlook, the production of such drugs would only suffice for about 100 million people – under 10% of those who need them, according to the WHO. The advice encourages countries and companies to widen access, via approaches such as patent sharing. A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in several nations in 2026. The Way Obesity Jabs Operate The injections imitate a natural hormone to reduce digestion speed, curb appetite and boost feelings of fullness so people reduce food intake. Patients typically begin shedding pounds in the initial weeks of commencing the regular doses. Studies suggests people may put most of the weight back on within a year of discontinuing the medication, because their typical appetite return. Being carrying excess weight elevates your risk for experiencing health problems, including diabetes, heart disease, stroke, and some cancers. Obesity concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.
Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs including Wegovy can access them, states the global health agency as it releases its initial advice on the drugs. With more than one billion people worldwide currently classified as obese, it is advocating for increased and just availability to GLP-1 medication. Based on projections, more than two billion will be living with obesity by 2030 if no action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be addressed with comprehensive and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and supply-chain constraints are major barriers to widespread access to the injections that can assist patients in reducing considerable body mass, notes the agency. Weight-Loss Drug Scarcity Even in the present best projected outlook, the production of such drugs would only suffice for about 100 million people – under 10% of those who need them, according to the WHO. The advice encourages countries and companies to widen access, via approaches such as patent sharing. A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in several nations in 2026. The Way Obesity Jabs Operate The injections imitate a natural hormone to reduce digestion speed, curb appetite and boost feelings of fullness so people reduce food intake. Patients typically begin shedding pounds in the initial weeks of commencing the regular doses. Studies suggests people may put most of the weight back on within a year of discontinuing the medication, because their typical appetite return. Being carrying excess weight elevates your risk for experiencing health problems, including diabetes, heart disease, stroke, and some cancers. Obesity concerns individuals in all nations and was linked to millions of fatalities worldwide in 2024, according to the health agency.